AR018311A1 - Compuestos de imidazopirazinas sustituidas con heterociclos, utiles como inhibidores de la proteina tirosina cinasa, las composiciones farmaceuticas quelos contienen y el procedimiento para preparar compuestos intermediarios en la sintesis de las mismas. - Google Patents
Compuestos de imidazopirazinas sustituidas con heterociclos, utiles como inhibidores de la proteina tirosina cinasa, las composiciones farmaceuticas quelos contienen y el procedimiento para preparar compuestos intermediarios en la sintesis de las mismas.Info
- Publication number
- AR018311A1 AR018311A1 ARP990100925A ARP990100925A AR018311A1 AR 018311 A1 AR018311 A1 AR 018311A1 AR P990100925 A ARP990100925 A AR P990100925A AR P990100925 A ARP990100925 A AR P990100925A AR 018311 A1 AR018311 A1 AR 018311A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- compounds
- ring
- unsubstituted
- forms
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se describen imidazopirazinas sustituidas con heterociclo y sales de las mismas, las composiciones farmacéuticas que contienen tales compuestos,y el método para preparar compuestos de síntesis. Dichos compuestos son utiles para el tratamiento de padecimiento asociados con la proteína tirosina cinasa,como desordenes inmunologicos. Dichas imidazopirazinas tienen la formula (I), donde:Q, junto con los átomos a los cuales está unido, forma unanillo heterocíclico de 5, 6 o 7 miembros; p es 0 o un entero de 1 a t, donde t = 3 cuando Q forma un anillo de 5 miembros, t = 4 cuando Q forma un anillode 6 miembros, y t = 5 cuando Q forma un anillo de 7 miembros; cada R1 y R2 y R3, se seleccionan independientemente de: (1) hidrogeno o R6, donde R6 esalquilo, alquenilo, alquinilo, cicloalquilo, cicloalquilalquilo, cicloalquenilo, cicloalquenilalquilo, arilo, aralquilo, heterociclo, o heterocicloalquilo,cada uno de los cuales no sustituido o sustituido con Z1, Z2 y uno o más grupos Z3; (2) -OH o -OR6; (3) -SH o -SR6; (4) -C(O)qH, -C(O)qR6, o -O-C(O)qR6, dondeq es 1 o 2; (5) -SO3H o S(O)qR6;(6) halo; (7) ciano; (8) nitro; (9) -Z4-NR7R8; (10) -Z4-N(R9)-Z5-NR10R11; (11) -Z4-N(R12)-Z5-R6; (12) -SiR13R14R15; (13)-P(O)(OR6)2; (14) cualquier de los dosgrupos R1 pueden conjuntamente ser alquileno o alquenileno que completan un anillo saturado o no saturado de 3 a 8miembros junto con los átomos de C al cual están unidos, el cual anillo está no sustituido o sustituido con Z1, Z2 y Z3; o (15) cualquiera de los dos gruposR1 pueden, conjuntamente con los átomos a los cuales están unidos, formar un grupo heterociclo, el cual grupo está no sustituido o sustituido con Z1, Z2 yZ3; R4 y R5: (1) son cada uno independientemente hidrogeno, R6, o -C(O)R6;o (2) junto con el átomo de nitrogeno al cual están unidos completan un anilloheterocíclico no saturado o saturado de 3 a 8 miembros el cual está no sustituido o sustituido con Z1, Z2 y Z3, el cual anillo heterocíclico puedeopcionalmente estar fusionado con un anillo de benceno que a su vez está no sustituido o sustituido con Z1, Z2 y Z3; R7, R8,R9, R10, R11 y R12:
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7678998P | 1998-03-04 | 1998-03-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR018311A1 true AR018311A1 (es) | 2001-11-14 |
Family
ID=22134195
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP990100925A AR018311A1 (es) | 1998-03-04 | 1999-03-04 | Compuestos de imidazopirazinas sustituidas con heterociclos, utiles como inhibidores de la proteina tirosina cinasa, las composiciones farmaceuticas quelos contienen y el procedimiento para preparar compuestos intermediarios en la sintesis de las mismas. |
Country Status (11)
Country | Link |
---|---|
US (1) | US5990109A (es) |
EP (1) | EP1066286B1 (es) |
JP (1) | JP2002505330A (es) |
AR (1) | AR018311A1 (es) |
AT (1) | ATE430149T1 (es) |
AU (1) | AU756838B2 (es) |
CA (1) | CA2322311C (es) |
DE (1) | DE69940808D1 (es) |
ES (1) | ES2324846T3 (es) |
WO (1) | WO1999045009A1 (es) |
ZA (1) | ZA991721B (es) |
Families Citing this family (138)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020019346A1 (en) * | 1997-05-21 | 2002-02-14 | Children's Medical Center Corporation | Treatment of prostate cancer by inhibiting lyn tyrosine kinase |
US7354894B2 (en) | 1998-08-18 | 2008-04-08 | The Regents Of The University Of California | Preventing airway mucus production by administration of EGF-R antagonists |
PL200940B1 (pl) | 1998-08-18 | 2009-02-27 | Univ California | Zastosowanie antagonisty receptora naskórkowego czynnika wzrostowego (EGF-R) i postać farmaceutyczna do leczenia nadmiernego wydzielania śluzu dróg oddechowych |
US20030119895A1 (en) * | 1998-12-23 | 2003-06-26 | Pharmacia Corporation | Methods using a combination of a 3-heteroaryl-2-indolinone and a cyclooxygenase-2 inhibitor for the treatment of neoplasia |
US20040038948A1 (en) * | 1999-12-07 | 2004-02-26 | Uhrich Kathryn E. | Therapeutic compositions and methods |
US20010055593A1 (en) * | 2000-03-14 | 2001-12-27 | Joseph Sypek | Use of rapamycin and agents that inhibit B7 activity in immunomodulation |
HUP0302925A3 (en) | 2000-10-03 | 2004-10-28 | Bristol Myers Squibb Co | Amino-substituted tetracyclic compouds useful as anti-inflammatory agents and pharmaceutical compositions comprising same |
US20040102455A1 (en) * | 2001-01-30 | 2004-05-27 | Burns Christopher John | Method of inhibiting kinases |
JP2004517638A (ja) * | 2001-02-02 | 2004-06-17 | マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ | 機能的核酸の同定方法 |
WO2002096374A2 (en) | 2001-05-31 | 2002-12-05 | Upsher-Smith Laboratories, Inc. | Dermatological compositions and methods comprising alpha-hydroxy acids or derivatives |
US7338969B2 (en) * | 2002-03-08 | 2008-03-04 | Quonova, Llc | Modulation of pathogenicity |
US7335779B2 (en) * | 2002-03-08 | 2008-02-26 | Quonova, Llc | Modulation of pathogenicity |
WO2004004644A2 (en) * | 2002-07-05 | 2004-01-15 | Beth Israel Deaconess Medical Center | Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms |
US8729107B2 (en) * | 2002-12-06 | 2014-05-20 | Purdue Research Foundation | Pyridines for treating injured mammalian nerve tissue |
WO2004052291A2 (en) * | 2002-12-06 | 2004-06-24 | Purdue Research Foundation | Pyridines for treating injured mammalian nerve tissue |
US20040180898A1 (en) * | 2003-03-03 | 2004-09-16 | Bang-Chi Chen | Processes for preparing imidazoquinoxalinones, heterocyclic-substituted imidazopyrazinones, imidazoquinoxalines and heterocyclic-substituted imidazopyrazines |
WO2004100868A2 (en) * | 2003-04-23 | 2004-11-25 | Abbott Laboratories | Method of treating transplant rejection |
US20070196340A1 (en) * | 2003-05-06 | 2007-08-23 | Aldo Ammendola | Modulation of Pathogenicity |
NZ544797A (en) | 2003-07-18 | 2011-04-29 | Amgen Fremont Inc | Specific antibodies that bind HGF and neutralise binding of HGF to met |
DE602004004665T2 (de) * | 2003-08-20 | 2008-01-03 | Pharmacyclics, Inc., Sunnyvale | Acetylenderivate als inhibitoren von histondeacetylase |
US7517991B2 (en) * | 2004-10-12 | 2009-04-14 | Bristol-Myers Squibb Company | N-sulfonylpiperidine cannabinoid receptor 1 antagonists |
JP5089392B2 (ja) * | 2004-10-13 | 2012-12-05 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | キナーゼ阻害剤としての複素環式置換ビスアリール尿素誘導体 |
WO2006060318A2 (en) | 2004-11-30 | 2006-06-08 | Amgen Inc. | Quinolines and quinazoline analogs and their use as medicaments for treating cancer |
WO2006076597A1 (en) * | 2005-01-12 | 2006-07-20 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoid receptor modulators |
US7314882B2 (en) * | 2005-01-12 | 2008-01-01 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoid receptor modulators |
US7361766B2 (en) | 2005-01-12 | 2008-04-22 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoid receptor modulators |
US20060160850A1 (en) * | 2005-01-18 | 2006-07-20 | Chongqing Sun | Bicyclic heterocycles as cannabinoid receptor modulators |
ATE421518T1 (de) * | 2005-02-10 | 2009-02-15 | Bristol Myers Squibb Co | Dihydrochinazolinone als 5ht-modulatoren |
US7632837B2 (en) * | 2005-06-17 | 2009-12-15 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoid-1 receptor modulators |
US7572808B2 (en) * | 2005-06-17 | 2009-08-11 | Bristol-Myers Squibb Company | Triazolopyridine cannabinoid receptor 1 antagonists |
US20060287342A1 (en) * | 2005-06-17 | 2006-12-21 | Mikkilineni Amarendra B | Triazolopyrimidine heterocycles as cannabinoid receptor modulators |
US7629342B2 (en) * | 2005-06-17 | 2009-12-08 | Bristol-Myers Squibb Company | Azabicyclic heterocycles as cannabinoid receptor modulators |
US7452892B2 (en) * | 2005-06-17 | 2008-11-18 | Bristol-Myers Squibb Company | Triazolopyrimidine cannabinoid receptor 1 antagonists |
EA200800430A1 (ru) * | 2005-07-28 | 2008-06-30 | Бристол-Маерс Сквибб Компани | Замещённые тетрагидро-1н-пиридо[4,3,b] индолы как агонисты и антагонисты серотониновых рецепторов |
US7795436B2 (en) * | 2005-08-24 | 2010-09-14 | Bristol-Myers Squibb Company | Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists |
US20080108664A1 (en) | 2005-12-23 | 2008-05-08 | Liu Belle B | Solid-state form of AMG 706 and pharmaceutical compositions thereof |
EP1987023B1 (en) | 2006-02-10 | 2010-11-24 | Amgen, Inc | Hydrate forms of amg706 |
TW200815436A (en) * | 2006-05-30 | 2008-04-01 | Elbion Ag | 4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
PE20121506A1 (es) | 2006-07-14 | 2012-11-26 | Amgen Inc | Compuestos triazolopiridinas como inhibidores de c-met |
US8217177B2 (en) | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
CA2672612A1 (en) * | 2006-12-14 | 2008-06-26 | Vertex Pharmaceuticals Incorporated | Compounds useful as protein kinase inhibitors |
WO2008079291A2 (en) | 2006-12-20 | 2008-07-03 | Amgen Inc. | Substituted heterocycles and methods of use |
ES2449482T3 (es) | 2007-01-09 | 2014-03-19 | Amgen Inc. | Derivados de bis-aril-amida útiles para el tratamiento de cáncer |
US8314087B2 (en) | 2007-02-16 | 2012-11-20 | Amgen Inc. | Nitrogen-containing heterocyclyl ketones and methods of use |
WO2008130619A2 (en) * | 2007-04-20 | 2008-10-30 | Trustees Of Boston College | A composition comprising an inhibitor of pde4 and/or pde7 |
WO2009026303A1 (en) | 2007-08-21 | 2009-02-26 | Amgen Inc. | Human c-fms antigen binding proteins |
US20090143361A1 (en) * | 2007-11-30 | 2009-06-04 | Elbion Gmbh | Pyrido[3,2-E]Pyrazines, Process For Preparing The Same, And Their Use As Inhibitors Of Phosphodiesterase 10 |
WO2009070584A1 (en) | 2007-11-30 | 2009-06-04 | Wyeth | Aryl and heteroaryl fused imidazo[1,5-a]pyrazines as inhibitors of phosphodiesterase 10 |
US20090143392A1 (en) * | 2007-11-30 | 2009-06-04 | Elbion Gmbh | Methods of Treating Obesity and Metabolic Disorders |
TWI498115B (zh) * | 2007-12-27 | 2015-09-01 | Daiichi Sankyo Co Ltd | 咪唑羰基化合物 |
AU2009204483B2 (en) | 2008-01-04 | 2014-03-13 | Intellikine, Llc | Certain chemical entities, compositions and methods |
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
US20100227853A1 (en) * | 2008-04-18 | 2010-09-09 | Trustees Of Boston College | Inhibitors of cyclic amp phosphodiesterases |
WO2009152133A1 (en) * | 2008-06-10 | 2009-12-17 | Abbott Laboratories | Novel tricyclic compounds |
JP5869338B2 (ja) | 2008-06-23 | 2016-02-24 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | タンパク質キナーゼ阻害剤 |
US20100075973A1 (en) * | 2008-08-28 | 2010-03-25 | Takeda Pharmaceutical Company Limited | Polo-like kinase inhibitors |
US20100136097A1 (en) * | 2008-12-02 | 2010-06-03 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Systems for modulating inflammation |
US20100135983A1 (en) * | 2008-12-02 | 2010-06-03 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Anti-inflammatory compositions and methods |
US20100136096A1 (en) * | 2008-12-02 | 2010-06-03 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Systems for modulating inflammation |
US20100136094A1 (en) * | 2008-12-02 | 2010-06-03 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Systems for modulating inflammation |
US20100137246A1 (en) * | 2008-12-02 | 2010-06-03 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Anti-inflammatory compositions and methods |
US20100135908A1 (en) * | 2008-12-02 | 2010-06-03 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Delivery devices for modulating inflammation |
US20100136095A1 (en) * | 2008-12-02 | 2010-06-03 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Systems for modulating inflammation |
US8361962B2 (en) * | 2009-07-27 | 2013-01-29 | Roche Palo Alto Llc | Tricyclic inhibitors of JAK |
US8435976B2 (en) * | 2009-09-08 | 2013-05-07 | F. Hoffmann-La Roche | 4-substituted pyridin-3-yl-carboxamide compounds and methods of use |
BR112012005382A2 (pt) | 2009-09-10 | 2016-03-29 | Hoffmann La Roche | inibidores de jak |
BR112012006176A2 (pt) | 2009-09-21 | 2015-09-08 | Hoffmann La Roche | inibidores macrocíclicos de jak |
SI2506716T1 (sl) | 2009-12-01 | 2017-10-30 | Abb Vie Inc. | Nove triciklične spojine |
US8785639B2 (en) | 2009-12-01 | 2014-07-22 | Abbvie Inc. | Substituted dihydropyrazolo[3,4-D]pyrrolo[2,3-B]pyridines and methods of use thereof |
EP2507267B1 (en) * | 2009-12-02 | 2016-09-14 | Acceleron Pharma, Inc. | Compositions and methods for increasing serum half-life of fc fusion proteins |
WO2011161217A2 (en) | 2010-06-23 | 2011-12-29 | Palacký University in Olomouc | Targeting of vegfr2 |
BR112013017670B1 (pt) | 2011-01-10 | 2022-07-19 | Infinity Pharmaceuticals, Inc | Processos de preparação de isoquinolinonas e formas sólidas de isoquinolinonas |
PT2688887E (pt) | 2011-03-23 | 2015-07-06 | Amgen Inc | Inibidores duais tricíclicos fusionados de cdk 4/6 e flt3 |
EP2718328A4 (en) | 2011-06-08 | 2014-12-24 | Acceleron Pharma Inc | COMPOSITIONS AND METHODS FOR INCREASING THE HALF TIME OF SERUM |
US9745288B2 (en) | 2011-08-16 | 2017-08-29 | Indiana University Research And Technology Corporation | Compounds and methods for treating cancer by inhibiting the urokinase receptor |
RU2628074C2 (ru) * | 2011-09-30 | 2017-08-14 | Си энд Си РИСЕРЧ ЛЭБОРЕТРИЗ | ТРИЦИКЛИЧЕСКИЕ АЗОТСОДЕРЖАЩИЕ ПРОИЗВОДНЫЕ ИМИДАЗО[4,5-с]ПИРИДИНА, ОБЛАДАЮЩИЕ ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ РЕЦЕПТОРА ГИСТАМИНА 4 (hH4R) |
AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
EP2852594B1 (en) | 2012-05-21 | 2016-05-11 | Allergan, Inc. | Pyrimidino[1,2-c]quinazolinone derivatives as tyrosine kinases inhibitors |
US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
US9505749B2 (en) | 2012-08-29 | 2016-11-29 | Amgen Inc. | Quinazolinone compounds and derivatives thereof |
US9387250B2 (en) | 2013-03-15 | 2016-07-12 | Rutgers, The State University Of New Jersey | Therapeutic compositions for bone repair |
US20150320755A1 (en) | 2014-04-16 | 2015-11-12 | Infinity Pharmaceuticals, Inc. | Combination therapies |
US11524964B2 (en) | 2015-10-16 | 2022-12-13 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11773106B2 (en) | 2015-10-16 | 2023-10-03 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11365198B2 (en) | 2015-10-16 | 2022-06-21 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
BR122022024925B1 (pt) | 2015-10-16 | 2023-11-28 | Abbvie Inc | Composição farmacêutica de liberação prolongada compreendendo (3s,4r)-3-etil-4-(3h-imidazo[1,2-a]pirrolo[2,3-e]pirazin-8-il)-n-(2,2,2-trifluoroetil) pirroli-dina-1-carboxamida |
US11512092B2 (en) | 2015-10-16 | 2022-11-29 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US10550126B2 (en) | 2015-10-16 | 2020-02-04 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
EP3414236A1 (de) | 2016-02-11 | 2018-12-19 | Bayer CropScience Aktiengesellschaft | Substituierte 2-(het)aryl-imidazolyl-carboxyamide als schädlingsbekämpfungsmittel |
AU2017281797A1 (en) | 2016-06-24 | 2019-01-24 | Infinity Pharmaceuticals, Inc. | Combination therapies |
JOP20190154B1 (ar) | 2016-12-22 | 2022-09-15 | Amgen Inc | بنز أيزو ثيازول، أيزو ثيازولو [3، 4-b] بيريدين، كينازولين، فثالازين، بيريدو [2، 3-d] بيريدازين ومشتقات بيريدو [2، 3-d] بيريميدين على هيئة مثبطات kras g12c لمعالجة سرطان الرئة، أو سرطان البنكرياس أو سرطان القولون والمستقيم |
JOP20190272A1 (ar) | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
ES2928576T3 (es) | 2017-09-08 | 2022-11-21 | Amgen Inc | Inhibidores de KRAS G12C y métodos de uso de los mismos |
MA52501A (fr) | 2018-05-04 | 2021-03-10 | Amgen Inc | Inhibiteurs de kras g12c et leurs procédés d'utilisation |
MA52496A (fr) | 2018-05-04 | 2021-03-10 | Amgen Inc | Inhibiteurs de kras g12c et leurs procédés d'utilisation |
MX2020011907A (es) | 2018-05-10 | 2021-01-29 | Amgen Inc | Inhibidores de kras g12c para el tratamiento de cancer. |
CA3098885A1 (en) | 2018-06-01 | 2019-12-05 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
EP3802537A1 (en) | 2018-06-11 | 2021-04-14 | Amgen Inc. | Kras g12c inhibitors for treating cancer |
JP7369719B2 (ja) | 2018-06-12 | 2023-10-26 | アムジエン・インコーポレーテツド | KRas G12C阻害剤及びそれを使用する方法 |
JP2020090482A (ja) | 2018-11-16 | 2020-06-11 | アムジエン・インコーポレーテツド | Kras g12c阻害剤化合物の重要な中間体の改良合成法 |
CA3117222A1 (en) | 2018-11-19 | 2020-05-28 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法 |
CA3123044A1 (en) | 2018-12-20 | 2020-06-25 | Amgen Inc. | Heteroaryl amides useful as kif18a inhibitors |
MX2021007104A (es) | 2018-12-20 | 2021-08-11 | Amgen Inc | Inhibidores de kif18a. |
MA54543A (fr) | 2018-12-20 | 2022-03-30 | Amgen Inc | Inhibiteurs de kif18a |
JP2022513967A (ja) | 2018-12-20 | 2022-02-09 | アムジエン・インコーポレーテツド | Kif18a阻害剤として有用なヘテロアリールアミド |
CN113767100A (zh) | 2019-03-01 | 2021-12-07 | 锐新医药公司 | 双环杂芳基化合物及其用途 |
WO2020180770A1 (en) | 2019-03-01 | 2020-09-10 | Revolution Medicines, Inc. | Bicyclic heterocyclyl compounds and uses thereof |
EP3738593A1 (en) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosing of kras inhibitor for treatment of cancers |
CN114144414A (zh) | 2019-05-21 | 2022-03-04 | 美国安进公司 | 固态形式 |
AU2020324963A1 (en) | 2019-08-02 | 2022-02-24 | Amgen Inc. | KIF18A inhibitors |
JP2022542392A (ja) | 2019-08-02 | 2022-10-03 | アムジエン・インコーポレーテツド | Kif18a阻害剤としてのピリジン誘導体 |
CN114302880A (zh) | 2019-08-02 | 2022-04-08 | 美国安进公司 | Kif18a抑制剂 |
CA3147272A1 (en) | 2019-08-02 | 2021-02-11 | Amgen Inc. | Kif18a inhibitors |
MX2022004656A (es) | 2019-10-24 | 2022-05-25 | Amgen Inc | Derivados de piridopirimidina utiles como inhibidores de kras g12c y kras g12d en el tratamiento del cancer. |
BR112022008565A2 (pt) | 2019-11-04 | 2022-08-09 | Revolution Medicines Inc | Composto, composição farmacêutica, conjugado, métodos para tratar câncer e um distúrbio relativo à proteína ras |
TW202132315A (zh) | 2019-11-04 | 2021-09-01 | 美商銳新醫藥公司 | Ras 抑制劑 |
JP2022553859A (ja) | 2019-11-04 | 2022-12-26 | レボリューション メディシンズ インコーポレイテッド | Ras阻害剤 |
CN114901662A (zh) | 2019-11-08 | 2022-08-12 | 锐新医药公司 | 双环杂芳基化合物及其用途 |
MX2022005708A (es) | 2019-11-14 | 2022-06-08 | Amgen Inc | Sintesis mejorada del compuesto inhibidor de g12c de kras. |
MX2022005726A (es) | 2019-11-14 | 2022-06-09 | Amgen Inc | Sintesis mejorada del compuesto inhibidor de g12c de kras. |
CN114980976A (zh) | 2019-11-27 | 2022-08-30 | 锐新医药公司 | 共价ras抑制剂及其用途 |
JP2023509701A (ja) | 2020-01-07 | 2023-03-09 | レヴォリューション・メディスンズ,インコーポレイテッド | Shp2阻害剤投薬およびがんを処置する方法 |
IL299131A (en) | 2020-06-18 | 2023-02-01 | Revolution Medicines Inc | Methods for delaying, preventing and treating acquired resistance to RAS inhibitors |
EP4208261A1 (en) | 2020-09-03 | 2023-07-12 | Revolution Medicines, Inc. | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
EP4214209A1 (en) | 2020-09-15 | 2023-07-26 | Revolution Medicines, Inc. | Indole derivatives as ras inhibitors in the treatment of cancer |
AR124449A1 (es) | 2020-12-22 | 2023-03-29 | Qilu Regor Therapeutics Inc | Inhibidores de sos1 y usos de los mismos |
KR102615822B1 (ko) * | 2021-04-23 | 2023-12-19 | 재단법인 대구경북첨단의료산업진흥재단 | 이미다조[1,5-a]피리도[3,2-e]피라진 유도체 화합물 및 이를 유효성분으로 함유하는 암 또는 자가면역질환의 예방 또는 치료용 약학적 조성물 |
WO2022235866A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
EP4334321A1 (en) | 2021-05-05 | 2024-03-13 | Revolution Medicines, Inc. | Ras inhibitors |
CN117616031A (zh) | 2021-05-05 | 2024-02-27 | 锐新医药公司 | 用于治疗癌症的ras抑制剂 |
AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
WO2023114954A1 (en) | 2021-12-17 | 2023-06-22 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
WO2024081916A1 (en) | 2022-10-14 | 2024-04-18 | Black Diamond Therapeutics, Inc. | Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives |
US11905290B1 (en) | 2023-09-05 | 2024-02-20 | King Faisal University | 5-substituted aminopyrimido[6′,1′:2,3]imidazo[4,5-c][1,6]naphthyridine compounds as CK2 inhibitors |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4191767A (en) * | 1977-01-07 | 1980-03-04 | Westwood Pharmaceuticals, Inc. | Method for treating fungal infection in mammals with imidazo [1,2-a]quinoxalines |
US4225724A (en) * | 1977-01-07 | 1980-09-30 | Westwood Pharmaceuticals, Inc. | 1-(2-Phenylureylene)imidazoles |
US4236015A (en) * | 1977-01-07 | 1980-11-25 | Westwood Pharmaceuticals, Inc. | 1-(2-Acylaminophenyl)imidazoles |
US4229452A (en) * | 1977-01-07 | 1980-10-21 | Westwood Pharmaceuticals, Inc. | Treatment of inflammatory disorders with 4-trifluoromethylimidazo[1,2-a]quinoxaline |
US4197403A (en) * | 1977-01-07 | 1980-04-08 | Westwood Pharmaceuticals Inc. | 4-Aminosubstituted imidazo(1,2-A)quinoxalines |
US4172947A (en) * | 1977-01-07 | 1979-10-30 | Westwood Pharmaceuticals, Inc. | 1-(2-Acylaminophenyl)imidazoles |
US4191766A (en) * | 1977-01-07 | 1980-03-04 | Westwood Pharmaceuticals, Inc. | Method for reducing immunological response |
US4200750A (en) * | 1977-01-07 | 1980-04-29 | Westwood Pharmaceuticals Inc. | 4-Substituted imidazo [1,2-a]quinoxalines |
US4160097A (en) * | 1977-01-07 | 1979-07-03 | Westwind Pharmaceuticals, Inc. | 1-(2-Phenylureylene)imidazoles |
US4198508A (en) * | 1977-01-07 | 1980-04-15 | Westwood Pharmaceuticals Inc. | Process for preparing 4-substituted imidazo[1,2-a]quinoxalines |
JPS5632549A (en) * | 1979-08-27 | 1981-04-02 | Toyo Ink Mfg Co Ltd | Pigment composition |
US4440929A (en) * | 1981-07-16 | 1984-04-03 | Usv Pharmaceutical Corporation | Imidazoquinoxaline compounds |
DK161148C (da) * | 1988-06-14 | 1991-11-18 | Novo Nordisk As | Imidazoquinoxalinforbindelser, fremgangsmaade til fremstilling deraf samt farmaceutiske praeprater indeholdende forbindelserne |
US5276028A (en) * | 1990-06-22 | 1994-01-04 | Nordisk A/S | Imidazoquinoxaline compounds |
EP0562440B1 (en) * | 1992-03-18 | 1998-12-23 | Takeda Chemical Industries, Ltd. | Imidazopyridazines as antiasthmatics |
DE19506742A1 (de) * | 1995-02-27 | 1996-08-29 | Bayer Ag | Verwendung von Chinoxalinen in Kombination mit Protease-Inhibitoren als Arzneimittel zur Behandlung von AIDS und/oder HIV-Infektionen |
IT1276167B1 (it) * | 1995-11-24 | 1997-10-27 | Foscama Biomed Chim Farma | Imidazo(1,2-alfa)chinossalin-4-ammine attivi come antagonisti adenosinici,procedimento per la loro preparazione e loro composizioni |
US6235740B1 (en) * | 1997-08-25 | 2001-05-22 | Bristol-Myers Squibb Co. | Imidazoquinoxaline protein tyrosine kinase inhibitors |
US6635626B1 (en) * | 1997-08-25 | 2003-10-21 | Bristol-Myers Squibb Co. | Imidazoquinoxaline protein tyrosine kinase inhibitors |
-
1999
- 1999-03-01 WO PCT/US1999/004499 patent/WO1999045009A1/en active IP Right Grant
- 1999-03-01 AU AU33137/99A patent/AU756838B2/en not_active Ceased
- 1999-03-01 DE DE69940808T patent/DE69940808D1/de not_active Expired - Fee Related
- 1999-03-01 CA CA002322311A patent/CA2322311C/en not_active Expired - Fee Related
- 1999-03-01 ES ES99937929T patent/ES2324846T3/es not_active Expired - Lifetime
- 1999-03-01 JP JP2000534551A patent/JP2002505330A/ja active Pending
- 1999-03-01 EP EP99937929A patent/EP1066286B1/en not_active Expired - Lifetime
- 1999-03-01 AT AT99937929T patent/ATE430149T1/de not_active IP Right Cessation
- 1999-03-03 ZA ZA9901721A patent/ZA991721B/xx unknown
- 1999-03-04 AR ARP990100925A patent/AR018311A1/es unknown
- 1999-03-04 US US09/262,525 patent/US5990109A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
DE69940808D1 (de) | 2009-06-10 |
AU756838B2 (en) | 2003-01-23 |
JP2002505330A (ja) | 2002-02-19 |
ZA991721B (en) | 2000-10-10 |
EP1066286B1 (en) | 2009-04-29 |
ATE430149T1 (de) | 2009-05-15 |
CA2322311C (en) | 2009-10-13 |
AU3313799A (en) | 1999-09-20 |
EP1066286A4 (en) | 2004-02-11 |
EP1066286A1 (en) | 2001-01-10 |
WO1999045009A1 (en) | 1999-09-10 |
CA2322311A1 (en) | 1999-09-10 |
ES2324846T3 (es) | 2009-08-17 |
US5990109A (en) | 1999-11-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR018311A1 (es) | Compuestos de imidazopirazinas sustituidas con heterociclos, utiles como inhibidores de la proteina tirosina cinasa, las composiciones farmaceuticas quelos contienen y el procedimiento para preparar compuestos intermediarios en la sintesis de las mismas. | |
AR017588A1 (es) | Compuestos de benzotiazol, inhibidores de la proteina tirosina quinasa, metodo para tratar desordenes asociados con dicha proteina, y las composicionesfarmaceuticas que contienen dichos compuestos | |
CO2021003298A2 (es) | Compuestos de sulfonamidaurea novedosos | |
UY28026A1 (es) | 4-piperazinilbencenosulfonilindoles y usos de los mismos. | |
UY26968A1 (es) | Agentes terapéuticos | |
PE20220931A1 (es) | Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina | |
AR023659A1 (es) | Un compuesto inhibidor de p38, una composicion farmaceutica que lo comprende y el uso de dicha composicion en el tratamiento y prevencion de estados patologicos | |
BR0014137A (pt) | Composto, método para inibir a aurora 2 quinase em um animal de sangue quente, uso de um composto, e, composição farmacêutica | |
PA8546601A1 (es) | Nuevos derivados de indol con afinidad por el receptor 5-ht6 | |
ES2094721T3 (es) | Analogos de la camptotecina solubles en agua. | |
PA8547901A1 (es) | Derivados de 4-piperacinilindol con afinidad receptora de 5-ht6 | |
DK0652868T3 (da) | Hæmmere af c-AMP-phosphodiesterase | |
ID27535A (id) | Turunan pirasola sebagai inhibitor p-38 map kinase | |
AR051735A1 (es) | Inhibidores pirrolicos de la proteina quinasa erk, sintesis e intermediarios de los mismos. | |
ATE267200T1 (de) | Bicyclische kinase inhibitoren | |
PE108898A1 (es) | Derivados 6,5-heterobiciclicos sustituidos | |
CO5271715A1 (es) | 7-aza-indolin-2-onas sustituidas en 4 y su uso como inhibidores de proteiuna quinasa | |
ES2122764T3 (es) | Inhibidor de la proteina quinasa c. | |
EA200200716A1 (ru) | Арилконденсированные азаполициклические соединения | |
AR004219A1 (es) | Nuevos derivados de quinazolina, procedimientos para su preparacion, composiciones que los contienen y su uso en la preparacion de medicamentos,particularmente en el tratamiento de trastornos inflamatorios | |
ES2163295T3 (es) | Derivados de imidazol y su uso como inhibidores de la farnesil-protein-transferasa. | |
AR043436A1 (es) | Tetrahidroisoquinolinas sustituidas para uso como moduladores 5-ht6 | |
AR024060A1 (es) | Nuevos compuestos farmaceuticamente activos | |
BR0014225A (pt) | Derivados de pirazol | |
AR012489A1 (es) | Tiofenopiridinas antagonistas del factor de liberacion de corticotropina. procedimiento para su preparacion, el uso de las mismas en la preparacionde un medicamento, composicion farmaceutica que las comprende, procedimiento para la preparacion de dicha composicion, un compuesto intermediario y |